Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines

Nature Communications

Volumn 7, Issue , 2016, Pages

  Du, Lanying ^a   Tai, Wanbo ^a,b   Yang, Yang ^c   Zhao, Guangyu ^b   Zhu, Qing ^b   Sun, Shihui ^b   Liu, Chang ^c   Tao, Xinrong ^d   Tseng, Chien Te K ^d   Perlman, Stanley ^e   Jiang, Shibo ^a,f   Zhou, Yusen ^b   Li, Fang ^c  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; GLYCAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; RECEPTOR PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; CORONAVIRUS SPIKE GLYCOPROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

CHEMICAL BINDING; DESIGN METHOD; EXPERIMENTAL STUDY; GENETICALLY MODIFIED ORGANISM; IMMUNE RESPONSE; IMMUNE SYSTEM; INDEX METHOD; RODENT; VACCINE; VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NEUTRALIZING IMMUNOGENICITY INDEX; NONHUMAN; PROTEIN DOMAIN; RECEPTOR BINDING; SCORING SYSTEM; TRANSGENIC ANIMAL; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CORONAVIRUS INFECTION; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; PROTEIN SUBUNIT;

CORONAVIRUS; MUS MUSCULUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PROTEIN SUBUNITS; RECOMBINANT PROTEINS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 84996844201     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13473     Document Type: Article

References (49)

1. Kwong, P. D., Mascola, J. R., Nabel, G. J. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 1, a007278 (2011).
2. Dormitzer, P. R., Ulmer, J. B., Rappuoli, R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26, 659-667 (2008).
3. Kulp, D. W., Schief, W. R. Advances in structure-based vaccine design. Curr. Opin. Virol. 3, 322-331 (2013).
4. Dormitzer, P. R., Grandi, G., Rappuoli, R. Structural vaccinology starts to deliver. Nat. Rev. Microbiol. 10, 807-813 (2012).
5. Du, L. et al. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226-236 (2009).
6. Li, F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J. Virol. 89, 1954-1964 (2015).
7. Weaver, J. M. et al. Immunodominance of CD4 T cells to foreign antigens is peptide intrinsic and independent of molecular context: implications for vaccine design. J. Immunol. 181, 3039-3048 (2008).
8. Akram, A., Inman, R. D. Immunodominance: a pivotal principle in host response to viral infections. Clin. Immunol. 143, 99-115 (2012).
9. Patera, A. C., Graham, C. M., Thomas, D. B., Smith, C. A. Immunodominance with progenitor B cell diversity in the neutralizing antibody repertoire to influenza infection. Eur. J. Immunol. 25, 1803-1809 (1995).
10. Ito, H. O., Nakashima, T., So, T., Hirata, M., Inoue, M. Immunodominance of conformation-dependent B-cell epitopes of protein antigens. Biochem. Biophys. Res. Commun. 308, 770-776 (2003).
11. Garrity, R. R. et al. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 159, 279-289 (1997).
12. Schiffner, T. et al. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J. Virol. 87, 10163-10172 (2013).
13. Lin, G., Nara, P. L. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr. HIV Res. 5, 514-541 (2007).
14. De Groot, A. S., Moise, L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr. Opin. Drug. Discov. Devel. 10, 332-340 (2007).
15. Kessler, J. H. et al. BCR-ABL fusion regions as a source of multiple leukemiaspecific CD8\+ T-cell epitopes. Leukemia 20, 1738-1750 (2006).
16. Shirai, M. et al. CTL responses of HLA-A2. 1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLAA2. 1. J. Immunol. 154, 2733-2742 (1995).
17. Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966 (2003).
18. Peiris, J. S. M. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325 (2003).
19. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814-1820 (2012).
20. de Groot, R. J. et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J. Virol. 87, 7790-7792 (2013).
21. Wang, N. et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell. Res. 23, 986-993 (2013).
22. Lu, G. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500, 227-231 (2013).
23. Li, F., Li, W., Farzan, M., Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864-1868 (2005).
24. Chen, Y. et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J. Virol. 87, 10777-10783 (2013).
25. Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454 (2003).
26. Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254 (2013).
27. He, Y., Lu, H., Siddiqui, P., Zhou, Y., Jiang, S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 174, 4908-4915 (2005).
28. Du, L. et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 87, 9939-9942 (2013).
29. Du, L. et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25, 2832-2838 (2007).
30. Zhang, N., Jiang, S., Du, L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines 13, 761-774 (2014).
31. Kirchdoerfer, R. N. et al. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118-121 (2016).
32. Walls, A. C. et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531, 114-117 (2016).
33. Kornfeld, R., Kornfeld, S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54, 631-664 (1985).
34. Ma, C. et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-The importance of immunofocusing in subunit vaccine design. Vaccine 32, 6170-6176 (2014).
35. Pintar, A., Carugo, O., Pongor, S. CX, an algorithm that identifies protruding atoms in proteins. Bioinformatics 18, 980-984 (2002).
36. Du, L. et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J. Virol. 88, 7045-7053 (2014).
37. Ying, T. et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796-7805 (2014).
38. Ying, T. et al. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat. Commun. 6, 8223 (2015).
39. Qiu, H. et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antiviral. Res. 132, 141-148 (2016).
40. Ngwuta, J. O. et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl Med. 7, 309ra162 (2015).
41. Zhao, G. et al. Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome-coronavirus. PLoS ONE 10, e0145561 (2015).
42. Tao, X. et al. Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 90, 57-67 (2015).
43. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
44. Infante, Y. C., Pupo, A., Rojas, G. A combinatorial mutagenesis approach for functional epitope mapping on phage-displayed target antigen: application to antibodies against epidermal growth factor. mAbs 6, 637-648 (2014).
45. Rojas, G., Tundidor, Y., Infante, Y. C. High throughput functional epitope mapping: revisiting phage display platform to scan target antigen surface. mAbs 6, 1368-1376 (2014).
46. Malito, E. et al. Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc. Natl Acad. Sci. USA 110, 3304-3309 (2013).
47. Yang, Y. et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc. Natl Acad. Sci. USA 111, 12516-12521 (2014).
48. Aucouturier, J. et al. 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1, 111-118 (2002).
49. Montomoli, E. et al. Current adjuvants and new perspectives in vaccine formulation. Expert Rev. Vaccines 10, 1053-1061 (2011).